The objectives of central venous percutaneous transluminal angioplasty are to dilate the venous lesion and to extend the life of arteriovenous fistula for hemodialysis. It is reasonable to perform percutaneous transluminal angioplasty for central venous lesions if this interventional therapy is required to maintain stable dialysis therapy. However, the presence of large fresh thrombus at central venous lesion site represents a contraindication to percutaneous transluminal angioplasty unless the thrombus can first be removed by thrombectomy. Balloon angioplasty is a basic treatment for central venous lesion, but stent implantation is sometimes required. The self-expandable or balloon-expandable stent is chosen by the lesion location and characteristics. The lesion in subclavian vein is generally treated by self-expandable stent and right brachiocephalic vein is treated by balloon-expandable stent. The organic lesion of innominate vein with plaque is treated by self-expandable stent. Note that the innominate venous stenosis is sometimes caused by compression between the right brachiocephalic artery and the sternum, and this lesion is treated by balloon-expandable stent because the radial force of balloon-expandable stent is stronger than self-expandable stent. It is important to understand the indication and stent selection for central venous percutaneous transluminal angioplasty.
Introduction
Patients on chronic hemodialysis often develop central vein stenosis or occlusion (central venous lesions) in the hemodialysis access limb. The Guidelines for Vascular Access Construction and Repair in Chronic Hemodialysis Patients of the Japanese Society for Dialysis Therapy recommend percutaneous transluminal angioplasty (PTA) as a treatment for central venous lesions as well as for more distal arteriovenous fistulas (AVFs). [1] [2] [3] [4] [5] [6] [7] [8] [9] In general, central venous lesions refer to lesions in the cephalic arch, subclavian vein, brachiocephalic vein, and iliac vein.
We performed the endovascular interventional therapy for 221 central venous lesions of vascular access in [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] [2017] . The procedure success rate was 96.8% in all lesions and 87.8% for chronic totally occluded (CTO) lesions. The findings by intravascular ultrasound (IVUS) contribute very important information to accomplish PTA and avoid complications. 9 
Indication and contraindications of PTA for central venous lesions
It is reasonable to perform PTA for central venous lesion if this intervention is required to maintain stable dialysis therapy. However, the presence of large fresh thrombus at the lesion site represents a contraindication to PTA unless the thrombus can first be removed by thrombectomy or another method. The left brachiocephalic lesions can be due to not only compressive stenosis but also organic stenosis. In particular, the left brachiocephalic vein may be compressed between the sternum and the right brachiocephalic artery. 9 In Japan, no stents are currently available that are large enough to treat compressive lesions with a reference vein > 12 mm in size. Taken together with the high probability of stent dislocation from such lesions, PTA is contraindicated in this setting.
Indication for ballooning and stenting
Balloon angioplasty is the basic PTA technique for treating hemodialysis-related central venous lesions as well as venous lesions distal to the vascular access site. Stenting is needed if balloon angioplasty alone fails to achieve sufficient dilation of the lesion. 3, 4 Our current indications for ballooning and stenting in patients with central venous lesions are as follows:
1. Balloon angioplasty is indicated for primary stenosis and short CTOs. 2. If balloon angioplasty achieves insufficient dilation (e.g. severe recoil) or leads to dissection or acute occlusion of the affected vein, bail-out stenting is performed. 3. Elective stenting is indicated for frequent restenosis or a long CTO since it is expected to ensure sustained patency of the vein.
Stent selection
We select stents for central venous lesions according to the criteria shown in Figure 1 . The late outcome of stenting for central venous lesions is still not satisfactory. However, stenting needs to be considered for preserving the function of the access limb if balloon angioplasty alone does not seem likely to achieve prolonged patency of the affected vein.
Case presentation 1 . CTO of right subclavian vein (Figure 2 ). The AVF was produced in right forearm and the swelling of right upper arm was significantly increased. The angiography presented the totally occluded right subclavian vein. We performed bidirectional approach via right AVF and right femoral vein. The hard wire (Chevalier eq\o\ac(○, R) guidewire 15 g; Cardinal Health, Dublin, OH, USA) could cross the CTO lesion, and lesion was dilated by 2.0 and 6.0 mm balloon. The SMART eq\o\ac(○,R) stent (10 × 60 mm; Cardinal Health) was delivered and post-dilatation was performed by 8.0 mm-balloon with 10 atm. The stent diameter was 10 mm, but the final balloon size was 8 mm. The 7-or 8-mm-sized balloon is enough to achieve the improvement in symptoms, and larger sized ballooning may cause the perforation. 2. CTO of right brachiocephalic vein (organic occlusion; Figure 3) . A hemodialysis patient with AVF in the right forearm underwent three balloon PTA procedures for right brachiocephalic venous stenosis with frequent recurrence. An angiogram obtained at the most recent presentation showed total occlusion of the right brachiocephalic vein. The 0.014 in Treasure eq\o\ac(○,R) guidewire (Asahi Intecc, Nagoya, Japan) successfully crossed the lesion and was then advanced to the inferior vena cava to prevent entry into the right atrium or ventricle. After pre-dilatation of the CTO with a 2 mm balloon, IVUS showed passage of the guidewire through the center of the lumen. Since dilation of the CTO with a large balloon might have induced dissection or perforation, dilation of this lesion was initially attempted with a small balloon. The lesion was first dilated with a 4 mm balloon inflated at 8 atm. and then with a 6 mm balloon inflated at 8 atm. This CTO with restenosis at short intervals was a good indication for stenting, so an Express stent (8 × 37 mm, Boston Scientific, Marlborough, MA, USA) was gradually expanded with escalating pressures and eventually implanted at 8 atm. Post-stenting angiography confirmed that there was no venous injury. Both edges of the stent were additionally dilated with a 10 mm balloon inflated at 3 atm. to create a dog-bone configuration and thus prevent dislocation of the stent. Final angiography confirmed satisfactory dilation of the lesion.
CTO of left brachiocephalic vein with organic
plaque (Figure 4) . The multi-detector row computed tomography (MDCT) images presented the CTO lesions of the left brachiocephalic vein with intimal hyperplasia (organic plaque). The bidirectional approach was employed for this lesion to facilitate optimal location of the proximal edge of the stent to be implanted. A 0.035-in Radifocus ® guidewire (TRUMO, Tokyo, Japan) readily crossed the CTO. After pre-dilatation with a 4 mm balloon inflated at 6 atm., a SMART stent (10 × 60 mm) was placed at the lesion, and PTA was successfully completed by post-dilatation with a 7 mm balloon inflated at 6 atm.
Compressive stenosis of left brachiocephalic vein
( Figures 5 and 6 ). The MDCT images of left brachiocephalic vein stenosis due to compression between sternum and right brachiocephalic artery resulted in marked swelling of the access limb. the site of compression. Then, the proximal and distal edges of the stent were further expanded with a 10-mm balloon inflated at a low pressure to create the dog-bone configuration and thus prevent stent displacement. Final angiography and IVUS confirmed sufficient circular enlargement of the lumen. On the following day, MDCT further confirmed that the implanted stent was located between the right brachiocephalic artery and the sternum.
Conclusion
When PTA is performed for central venous stenosis or occlusion in the access limb of a dialysis patient, the objective is to dilate the venous lesion and to extend the life of the AVF for hemodialysis. Accordingly, we should be mindful that PTA is contraindicated for such venous lesions if it is likely to cause complications, especially life-threatening events. [10] [11] [12] [13] Interventionists who perform PTA for central venous lesions should thoroughly understand the indications and contraindications and should also be familiar with effective countermeasures for complications that may arise during intervention.
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